| FGF9 — Fibroblast Growth Factor 9 | |
|---|---|
| Symbol | FGF9 |
| Full Name | Fibroblast Growth Factor 9 (Glial-Activating Factor) |
| Chromosome | 13q12.11 |
| NCBI Gene | 2254 |
| Ensembl | ENSG00000157184 |
| OMIM | 135501 |
| UniProt | P31360 |
| Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Multiple Sclerosis |
| Expression | Brain, Lung, Heart, Kidney, Testis |
Fgf9 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FGF9 (Fibroblast Growth Factor 9), also known as Glial-Activating Factor (GAF), is a member of the FGF family originally identified for its ability to stimulate glial cell proliferation. Located on chromosome 13q12.11, FGF9 plays important roles in nervous system development and function [1][2].
FGF9 has distinct receptor binding properties compared to other FGFs, with particular affinity for FGFR3, making it unique in the family. In the adult brain, FGF9 continues to be expressed and participates in glial function and neural plasticity [3].
The FGF9 gene spans approximately 9 kb and consists of 3 exons. It encodes a protein of 208 amino acids with a molecular weight of approximately 23 kDa.
FGF9 is expressed in:
FGF9 binds preferentially to:
This specificity distinguishes FGF9 from other FGFs.
FGF9-FGFR3 activation triggers:
Glial Activation
Neuronal Survival
Myelination
FGF9 is implicated in AD:
Glial Response
Neuroinflammation
In PD:
FGF9 in MS:
FGF9 as a target:
The study of Fgf9 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.